ArticleMedical microbiology and immunology1994
Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.
Article in Medical microbiology and immunology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 70 citations in OpenAlex.
- Establishment and characterization of a genomic DNA reference material for Group B Streptococcus detection.Analytical and bioanalytical chemistry · 2026Article
- Review
- Group B streptococci (GBS) strains evading molecular diagnostics showed novel chromosomal deletions encompassing the CAMP-factor (cfb) encoding gene.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Analysis of molecular characteristics of CAMP-negativeFrontiers in microbiology · 2023Article
- Multicenter Evaluation of the Cepheid Xpert GBS LB XC Test.Journal of clinical microbiology · 2022Article
- Neutrophils discriminate live from dead bacteria by integrating signals initiated by Fprs and TLRs.The EMBO journal · 2022Article
- Article
- Research Advances on Tilapia Streptococcosis.Pathogens (Basel, Switzerland) · 2021Review
- Arginine Deiminase and Biotin Metabolism Signaling Pathways Play an Important Role in Human-Derived Serotype V, ST1 Streptococcus agalactiae Virulent Strain upon Infected Tilapia.Animals : an open access journal from MDPI · 2020Article
- Is a positive Christie-Atkinson-Munch-Peterson (CAMP) test sensitive enough for the identification of Streptococcus agalactiae?BMC infectious diseases · 2019Article
- Genome Analysis of Streptococcus pyogenes Associated with Pharyngitis and Skin Infections.PloS one · 2016Article
- Multicenter clinical evaluation of the Xpert GBS LB assay for detection of group B Streptococcus in prenatal screening specimens.Journal of clinical microbiology · 2015Article
- Interaction of Streptococcus agalactiae and Cellular Innate Immunity in Colonization and Disease.Frontiers in immunology · 2014Review
- SecA localization and SecA-dependent secretion occurs at new division septa in group B Streptococcus.PloS one · 2013Article
- Article
- High-level fluorescence labeling of gram-positive pathogens.PloS one · 2011Article
- Understanding the regulation of Group B Streptococcal virulence factors.Future microbiology · 2009Review
- Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR.Molecular microbiology · 2009Article
- Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae.Molecular microbiology · 2006Article
- Identification, cloning, and expression of the CAMP-like factor autotransporter gene (cfa) of Bartonella henselae.Infection and immunity · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An internal fragment of the cfb gene from group B streptococcal (GBS) strain R268 was amplified by polymerase chain reaction (PCR) using degenerate primers with sequences derived from the CAMP-factor amino acid (aa) sequence of GBS strain NCTC8181 [Rühlmann et al. (1988) FEBS Lett 235:262-266]. After cloning and sequencing this fragment, the remainder of cfb and the adjacent 5' and 3' sequences were amplified by inverted PCR of genomic DNA and directly sequenced from the PCR product. Within the 1560 bp sequenced, a complete cfb gene deviating in two deduced aa residues from the published sequence was identified. In addition, the cfbR268 sequence contained a 29-aa leader peptide. Using primers directed to the 5' and 3' ends of cfb for PCR, a cfb gene of uniform size could be detected in 19 clinical GBS isolates including three phenotypically CAMP-negative strains. Utilizing Northern blot analysis and primer extension assays, the cfbR268 promoter was located and the length of the cfb transcript was assessed at about 1100 bp. In a parallel experiment, no cfb transcript could be detected from the CAMP-negative GBS strain 74-360. The complete cfbR268 gene and different portions of its 5' and 3' ends were cloned into the plasmid pJLA602 and expressed in E. coli DH5 alpha. The recombinant peptides could be detected by Western immunoblots with polyclonal antiserum. Only the full-sized recombinant CAMP-factor was found to exert co-hemolytic activity in a sheep-blood agar assay. This co-hemolytic activity could be inhibited by anti-CAMP antiserum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.